Extracellular vesicles: a new frontier in diagnosing and treating graft-versus-host disease after allogeneic hematopoietic cell transplantation
Open Access
- 26 March 2025
- journal article
- review article
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 23 (1) , 1-22
Abstract
Graft-versus-host disease (GvHD) is a prevalent complication following allogeneic hematopoietic stem cell transplantation (HSCT) and is characterized by relatively high morbidity and mortality rates. GvHD can result in extensive systemic damage in patients following allogeneic HSCT (allo-HSCT), with the skin, gastrointestinal tract, and liver frequently being the primary target organs affected. The severe manifestations of acute intestinal GvHD often indicate a poor prognosis for patients after allo-HSCT. Endoscopy and histopathological evaluation remain employed to diagnose GvHD, and auxiliary examinations exclude differential diagnoses. Currently, reliable serum biomarkers for the diagnosis and differential diagnosis of GvHD are scarce. As an essential part of standard transplant protocols, early application of immunosuppressive drugs effectively prevents GvHD. Among them, steroids represent first-line therapeutic agents, and the JAK2 inhibitor ruxolitinib represents the second-line therapeutic agent. Currently, no efficacious treatment modality exists for steroid-resistant aGvHD. Therefore, the diagnosis and treatment of GvHD still face significant medical demands. Extracellular vesicles (EVs) are nanometer to micrometer-scale biomembrane vesicles containing various bioactive components, such as proteins, nucleotides, and metabolites. Distinctive changes in serum-derived EV components occur in patients after allo-HSCT; Hence, EVs are expected to be potential biomarkers for diagnosing and treating GvHD. Furthermore, cell-free therapeutics characterized by EVs derived from mesenchymal stem cells (MSCs) have manifested remarkable therapeutic efficacy in preclinical models and preclinical trials of GvHD. Customized engineered EVs with fewer toxic and side effects for the combined treatment of GvHD hold broad prospects for clinical translation. This review article examines the potential value of translating EVs into clinical applications for the diagnosis and treatment of GvHD. It summarizes the latest advancements and prospects of engineered EVs applying GvHD.Keywords
Funding Information
- National Natural Science Foundation of China (82303775)
- Natural Science Foundation of Anhui Province (2308085QH273)
- China Postdoctoral Science Foundation (2023M733398)
This publication has 122 references indexed in Scilit:
- Immunogenicity of Extracellular VesiclesAdvanced Materials, 2024
- Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approachesJournal of Extracellular Vesicles, 2024
- Updates in chronic graft‐versus‐host disease managementAmerican Journal of Hematology, 2023
- Requirements for human pluripotent stem cell derived small extracellular vesiclesInterdisciplinary Medicine, 2023
- Requirements for human mesenchymal stem cell‐derived small extracellular vesiclesInterdisciplinary Medicine, 2023
- Functional Extracellular Vesicles for Regenerative MedicineSmall, 2022
- Exosomes originating from MSCs stimulated with TGF‐β and IFN‐γ promote Treg differentiationJournal of Cellular Physiology, 2018
- Graft-Versus-Host Disease Amelioration by Human Bone Marrow Mesenchymal Stromal/Stem Cell-Derived Extracellular Vesicles Is Associated with Peripheral Preservation of Naive T Cell PopulationsStem Cells, 2017
- Bone Marrow-Derived Mesenchymal Stromal Cells Harness Purinergenic Signaling to Tolerize Human Th1 Cells In VivoStem Cells, 2014
- Are Therapeutic Human Mesenchymal Stromal Cells Compatible with Human Blood?Stem Cells, 2012